1. Home
  2. KELYB vs NGNE Comparison

KELYB vs NGNE Comparison

Compare KELYB & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kelly Services Inc. Class B

KELYB

Kelly Services Inc. Class B

SELL

Current Price

$22.67

Market Cap

770.7M

ML Signal

SELL

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$23.35

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KELYB
NGNE
Founded
1946
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
770.7M
744.9M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
KELYB
NGNE
Price
$22.67
$23.35
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $77.88
AVG Volume (30 Days)
8.6K
★ 354.4K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
★ 1.33%
N/A
EPS Growth
N/A
★ 0.93
EPS
★ 0.15
N/A
Revenue
★ $5,355,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.70
N/A
P/E Ratio
$150.60
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$8.38
$15.93
52 Week High
$125.00
$43.66

Technical Indicators

Market Signals
Indicator
KELYB
NGNE
Relative Strength Index (RSI) 51.89 33.35
Support Level $21.75 $16.88
Resistance Level $24.77 $23.35
Average True Range (ATR) 0.55 1.99
MACD -0.02 -0.14
Stochastic Oscillator 50.76 26.52

Price Performance

Historical Comparison
KELYB
NGNE

About KELYB Kelly Services Inc. Class B

Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: